Alpha Teknova, Inc.

What they do

Founded in 1996, Teknova manufactures custom, made-to-order reagents at its Hollister, California headquarters and ships directly from that warehouse, typically recognizing revenue on shipment. It reports two product categories, Lab Essentials and Clinical Solutions, spanning three product types: pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company is ISO 13485:2016 certified, which allows it to supply diagnostic and therapeutic applications, and it serves roughly 3,000 customers across pharma, biotech, CDMOs, in vitro diagnostic franchises, and academic and government research institutions.

Revenue drivers

• Lab Essentials — Largest category, including pre-poured media plates as well as liquid media and molecular biology reagents; revenue was $9.2 million in Q2 2026 (up 18%) and $17.6 million in the first half of 2026.
• Clinical Solutions — Second category covering liquid microbial culture media and molecular biology reagents used in diagnostic and therapeutic applications; revenue was $2.4 million in Q2 2026 (up 18%) and $4.6 million in the first half of 2026.
• Other — Smallest reporting line, at $0.6 million in Q2 2026 and $1.1 million in the first half of 2026.
• Geography — Revenue is concentrated in the United States; only 4.3% of Q2 2026 revenue and 4.5% of first-half 2026 revenue came from customers outside the U.S., and sales abroad are denominated in U.S. dollars.

Recent performance

Second quarter 2026 total revenue was $12.2 million, up 18% from $10.3 million in Q2 2025 and the first quarter above $12 million in company history. Lab Essentials and Clinical Solutions each grew 18% year over year, to $9.2 million and $2.4 million. Gross margin was 40.1% versus 38.7% a year earlier, with the improvement driven by higher revenue and partly offset by higher fixed-cost absorption from faster finished goods turns. Net loss narrowed to $3.2 million, or negative $0.06 per diluted share, from $3.6 million, or negative $0.07. First-half 2026 revenue was $23.3 million versus $20.1 million a year earlier, and cash used in operating activities in Q2 2026 was $0.5 million versus $2.1 million of cash used in the prior-year quarter.

Strategy

Management attributes results to investments in the commercial organization, facilities, and manufacturing systems and says it expects expenses to keep rising in future periods but at a slower rate. Stated priorities include hiring and retaining personnel, investing in processes and infrastructure to improve operating efficiency and expand capacity, ramping a new warehouse and distribution facility, building brand awareness through targeted marketing and strategic partnerships, and increasing selling and marketing spend to drive customer acquisition and channel relationships. In the second quarter of 2026 the company launched Build-Tek, an AI-powered custom order configurator following a beta release, which it describes as giving developers a faster path from preclinical to clinical manufacturing. It also raised 2026 revenue guidance and reduced expected full-year free cash outflow.

Risks

• Recent losses and going-concern language — The company has recorded annual net losses every year from 2021 through 2025 (ranging from $9.8 million to $47.5 million) and its own risk factors reference its recent history of losses and ability to continue as a going concern.
• Customer and receivables concentration risk — Teknova's risk disclosures specifically flag its ability to limit accounts receivable and credit risk exposure.
• Supplier dependence — The company relies on a limited number of suppliers for certain raw materials and has no long-term supply arrangements, ordering only on a purchase order basis.
• Macro and demand uncertainty — Management cites general economic, market, and business conditions and their impact on customer demand, and the Q2 2026 release ties confidence to the biotech market continuing to recover.

Outlook

Management raised full-year 2026 revenue guidance to $45–47 million and now expects full-year free cash outflow of less than $8 million, citing 18% revenue growth and a significant improvement in free cash outflow. The CEO said the quarter's results strengthen confidence in delivering long-term, sustainable growth as the biotech market continues to recover, while the company expects expenses to increase in future periods but at a slower rate.